A Research Study to Look at How Semaglutide Compared to Placebo Affects Diabetic Eye Disease in People With Type 2 Diabetes

About

Brief Summary

This study will look at the long-term effects of semaglutide (active medicine) on diabetic eye disease when compared to placebo (dummy medicine). The study will be performed in people with type 2 diabetes. Participants will either get semaglutide or placebo in addition to their diabetes medicines - which treatment the participant gets is decided by chance. Participants will inject the study medicine using a pen-injector. The medicine must be injected in a skin fold in the stomach, thigh or upper arm once a week. The study will last for 5 years.

Primary Purpose

Treatment

Study Type

Interventional

Phase

Phase III

Eligibility

Gender

All

Healthy Volunteers

Minimum Age

18 Years

Maximum Age

N/A

Inclusion Criteria:

Male or female, age greater than or equal to 18 years at the time of signing informed consent
Diagnosed with type 2 diabetes mellitus.
HbA1c of 7.0-10.0% (53-86 mmol/mol) (both inclusive).
Eye inclusion criteria (both eyes must meet all criteria):
Early Treatment Diabetic Retinopathy Study (ETDRS) level of 10-75 (both inclusive) evaluated by fundus photography and confirmed by central reading centre
No ocular or intraocular treatment for diabetic retinopathy or diabetic macular oedema six months prior to the day of screening.
No anticipated need for ocular or intraocular treatment for diabetic retinopathy or diabetic macular oedema within three months after randomisation.
Best-corrected visual acuity greater than or equal to 30 letters using the ETDRS visual acuity protocol
No previous treatment with pan-retinal laser photocoagulation
No substantial non-diabetic ocular condition that, in the opinion of the ophthalmologist, would impact diabetic retinopathy or diabetic macular oedema progression during the trial
No substantial media opacities that would preclude successful imaging

Exclusion Criteria:

Any of the following: myocardial infarction, stroke, hospitalization for unstable angina pectoris or transient ischaemic attack within the past 60 days prior to the day of screening
Planned coronary, carotid or peripheral artery revascularisation known on the day of screening
Subjects presently classified as being in New York Heart Association (NYHA) Class IV
Renal impairment measured as estimated Glomerular Filtration Rate (eGFR) value of eGFR less than 30 ml/min/1.73 m^2
Personal or first degree relative(s) history of multiple endocrine neoplasia type 2 or medullary thyroid carcinoma
Presence or history of malignant neoplasms within the past 5 years prior to the day of screening. Basal and squamous cell skin cancer and any carcinoma in-situ are allowed
Female who is pregnant, breast-feeding or intends to become pregnant or is of child-bearing potential and not using highly effective contraceptive methods
Concurrent treatment with any GLP-1 receptor agonist or DPP-4 inhibitor from randomisation.
Receipt of any investigational medicinal product within 30 days before screening
Previous participation in this trial. Participation is defined as randomisation
Known or suspected hypersensitivity to trial products or related products
Any disorder, which in the investigator's opinion might jeopardise subject's safety or compliance with the protocol

Join this Trial

Contact our clinical trial navigators for opportunities that may be suitable for you